<DOC>
	<DOCNO>NCT00442962</DOCNO>
	<brief_summary>The purpose study determine pregnancy-limited , short-term combination HIV treatment regimen -- use solely prevention mother child transmission HIV discontinue postpartum -- decrease effectiveness standard initial regimen anti-HIV drug subsequent treatment need .</brief_summary>
	<brief_title>HIV Treatment Reinitiation Women Who Received Anti-HIV Drugs Prevent Mother-to-Child Transmission HIV</brief_title>
	<detailed_description>Stopping restart highly active antiretroviral therapy ( HAART ) generally recommend potential allow drug-resistant HIV emerge . However , prevent mother-to-child transmission ( MTCT ) , HIV infect woman pregnant temporarily put HAART , even HIV treatment indicate time . It unknown short-term therapy affect viral response HAART later , permanent therapy clinically indicate . The purpose study determine HAART take prevent MTCT pregnancy effect ability standard initial regimen HAART suppress HIV viral load . &gt; &gt; &gt; &gt; &gt; &gt; Study follow-up last 48 week per participant . Participants take daily regimen efavirenz emtricitabine/tenofovir disoproxil fumarate . There 8 clinical visit study ; visit occur baseline Weeks 2 , 4 , 8 , 16 , 24 , 36 , 48 . At visit , physical exam , blood urine collection , pregnancy test occur . At visit , adherence , quality-of-life , birth control interview complete . &gt; &gt; &gt; &gt; &gt; &gt; Enrollment study last 47 participant join December 31 , 2009 , whichever come later .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>HIV1 infect Viral load 500 copies/mL Prior HAART 7 day , le 40 week least one previous pregnancy prevention MTCT HIV Clinical laboratory indication start HAART , opinion participant 's physician Certain laboratory value Willingness use acceptable form contraception Parent guardian willing provide inform consent , applicable Taking antiretroviral medication within 24 week prior study entry Evidence certain HIV1 RT mutation within 90 day prior study entry ( version 1.0 ) Evidence certain HIV1 RT mutation identify standard bulk viral population genotypic resistance test time prior study entry , available ( version 2.0 , 09/03/2009 ) Treatment time , reason nevirapine single agent OR addition part study regimen single agent fail regimen Use certain antihistamine , certain antiinfectives , cisapride , St John 's wort , midazolam , triazolam , dihydroergotamine , ergonovine , ergotamine , methylergonovine within 14 day prior study entry Use HIV vaccine , chronic systemic corticosteroid , interleukin , interferon , cytokine , investigational therapy within 30 day prior study entry Acute chronic therapy certain serious medical illness within 14 day study entry . Participants complete 7 day therapy judge clinically stable exclude . Cancer require systemic chemotherapy Known allergy/sensitivity study drug formulation Current drug alcohol use , opinion investigator , would interfere study Two consecutive HIV viral load 5,000 copies/mL 8 week follow initiation HAART pregnancy still receive HAART Two consecutive viral load 400 copies/mL 24 week follow initiation HAART pregnancy still receive HAART Current imprisonment involuntary incarceration medical facility psychiatric physical illness Pregnancy breastfeeding</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>